A Genome-Wide Association Study of Small Cell Lung Cancer.


Journal

Archivos de bronconeumologia
ISSN: 1579-2129
Titre abrégé: Arch Bronconeumol
Pays: Spain
ID NLM: 0354720

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 07 04 2023
revised: 03 07 2023
accepted: 07 07 2023
medline: 6 10 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: ppublish

Résumé

Small cell lung cancer (SCLC) comprises 10-15% of all lung cancer cases and is the most aggressive histological type. Survival is poor and the molecular landscape of this disease is extraordinarily complex. The objective of this paper was to perform a Genome-Wide Association Study (GWAS) of this disease using a case-control study specifically designed for small cell lung cancer (SCLC). Incident cases were consecutively recruited from 8 hospitals from different regions of Spain. Controls were recruited from the same hospitals using a frequency sampling based on age and sex distribution of cases. Biological samples were obtained along with detailed information on cases and controls lifestyle, including tobacco and radon exposure. We included 271 SCLC cases and 557 controls. We found evidence (p-values<10 This study provides biological evidence for pathways related to SCLC, offering novel loci for further research.

Identifiants

pubmed: 37500326
pii: S0300-2896(23)00223-5
doi: 10.1016/j.arbres.2023.07.008
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

645-650

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

José Ramón Enjo-Barreiro (JR)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain.

Alberto Ruano-Ravina (A)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Spain; Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain. Electronic address: alberto.ruano@usc.es.

Silvia Diz-de-Almeida (S)

Grupo de Medicina Xenómica CIBERER-Instituto de Salud Carlos III (U-711), Centro Singular de Investigación en Medicina Molecular y Enfermedades Cronicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Raquel Cruz (R)

Grupo de Medicina Xenómica CIBERER-Instituto de Salud Carlos III (U-711), Centro Singular de Investigación en Medicina Molecular y Enfermedades Cronicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

Inés Quintela (I)

Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.

Julia Rey-Brandariz (J)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain.

Ángel Carracedo (Á)

Grupo de Medicina Xenómica CIBERER-Instituto de Salud Carlos III (U-711), Centro Singular de Investigación en Medicina Molecular y Enfermedades Cronicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.

Karl Kelsey (K)

Department of Epidemiology and Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.

Mariano Provencio (M)

Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain.

Juan Barros-Dios (J)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Spain; Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain.

Leonor Varela-Lema (L)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Spain; Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain.

Mónica Pérez-Ríos (M)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Spain; Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH